Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Research & Development: €53.0 Mil (TTM As of Dec. 2025)


FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
79 GF Score
Price €4.52
GF Value €3.50
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co Research & Development?

Biocytogen Pharmaceuticals (Beijing) Co FRA:I54 -2.59% 79 Research & Development is €53.0 Mil as of Dec. 2025. GuruFocus rates FRA:I54 with a GF Score™ of 79/100 and a GF Value™ of €3.50 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Biocytogen Pharmaceuticals (Beijing) Co's Research & Development for the six months ended in Dec. 2025 was €27.8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €53.0 Mil.

Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Biocytogen Pharmaceuticals (Beijing) Co Research & Development Related Terms

Biocytogen Pharmaceuticals (Beijing) Co Research & Development Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co Research & Development Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 77.60 94.67 60.92 42.49 53.12

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 29.08 20.70 21.28 25.25 27.76
FRA:I54
79GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €53.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €53.0 Mil mean?
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Research & Development of €53.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors.
Is Biocytogen Pharmaceuticals (Beijing) Co's Research & Development too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Research & Development is €53.0 Mil. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Research & Development compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's Research & Development of €53.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current Research & Development is €53.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.50, compared to a current price of €4.52 — trading 29.1% above its estimated fair value. The current Research & Development is €53.0 Mil. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Research & Development is €53.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €4.52 is trading 29.1% above its estimated GF Value™ of €3.50. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Modestly Overvalued.

Key valuation signals for FRA:I54:

  • Research & Development: €53.0 Mil
  • GF Value™: €3.50 vs. price of €4.52 (29.1% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
79GF Score

Get the complete analysis for FRA:I54

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.52
Price
€3.50
GF Value